Skip to content

Supernus Pharmaceuticals SUPN Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1

Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 at other companies

Skyline Champion logo
Skyline ChampionSKY
$4.5M+535%
Intuitive Machines, Inc. logo
Intuitive Machines, Inc.LUNR
$521K
Healthcare Services Group logo
Healthcare Services GroupHCSG
-$100K0.0%
Rigetti Computing, Inc. logo
Rigetti Computing, Inc.RGTI
$0-100%
Repligen logo
RepligenRGEN
-$146K
AvePoint, Inc. logo
AvePoint, Inc.AVPT
-$54.5M-2,064%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.62B+62.8%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's business combination contingent consideration arrangements change in amount of contingent consideration liability1.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's business combination contingent consideration arrangements change in amount of contingent consideration liability1?
Supernus Pharmaceuticals (SUPN) reported business combination contingent consideration arrangements change in amount of contingent consideration liability1 of $2.39M in Q1 2026.
How has Supernus Pharmaceuticals's business combination contingent consideration arrangements change in amount of contingent consideration liability1 changed year-over-year?
Supernus Pharmaceuticals's business combination contingent consideration arrangements change in amount of contingent consideration liability1 decreased by 68.8% year-over-year, from $7.66M to $2.39M.
What is the long-term trend for Supernus Pharmaceuticals's business combination contingent consideration arrangements change in amount of contingent consideration liability1?
Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business combination contingent consideration arrangements change in amount of contingent consideration liability1 has grown at a 268.0% compound annual growth rate (CAGR), from -$510K to $25.42M.
What does business combination contingent consideration arrangements change in amount of contingent consideration liability1 mean?
This metric represents the periodic adjustment to the fair value of liabilities associated with earn-outs or milestone payments from past acquisitions. Changes in this amount reflect updates to management's expectations regarding the achievement of future performance targets or regulatory milestones. It serves as a key indicator of potential future cash outflows related to inorganic growth strategies.